|
|
|
|
|
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.China |
First Approval Date13 May 2025 |
|
MechanismFGF23 antagonists |
|
|
|
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
/ Not yet recruitingPhase 3 评价维拉苷酶β酶替代疗法对儿童人群的安全性和有效性的临床研究
[Translation] Clinical studies evaluating the safety and efficacy of vilanoside β-enzyme replacement therapy in children.
旨在评估 60 U/kg 维拉苷酶β用于2~11岁的未经治疗 GD1 或 GD3 儿童参与者,持续治疗9个月的安全性、有效性、PK、PD和免疫原性。
[Translation] The study aimed to evaluate the safety, efficacy, pharmacokinetics, PD, and immunogenicity of 60 U/kg vilanoside β in treatment-naïve children aged 2–11 years with GD1 or GD3 for 9 months.
100 Clinical Results associated with Beihai Kangcheng (Shanghai) Biotechnology Co., Ltd.
0 Patents (Medical) associated with Beihai Kangcheng (Shanghai) Biotechnology Co., Ltd.
100 Deals associated with Beihai Kangcheng (Shanghai) Biotechnology Co., Ltd.
100 Translational Medicine associated with Beihai Kangcheng (Shanghai) Biotechnology Co., Ltd.